Exploratory digital outcome measures of motor sign progression in Parkinson’s disease patients treated with prasinezumab

Digital health technology (DHT) tools for Parkinson's disease (PD) e.g., smartphones and wearables were used for remote and frequent measurement of motor signs in the phase 2 PASADENA study of the anti-alpha-synuclein monoclonal antibody prasinezumab. 316 early-stage PD participants were randomized to placebo, 1500 mg, or 4500 mg prasinezumab for 52 weeks; placebo participants were re-randomized to prasinezumab for the ensuing 52 weeks. Patients performed daily smartphone motor "active tests", and were passively monitored by smartphone/smartwatch throughout the day over 2 y. Change from baseline analyses censored data at dopaminergic treatment start. Bilateral speeded tapping variability and hand-turning, U-turn speed, passively monitored hand movement power, and summary Simple Sum scores progressed numerically less in prasinezumab-treated vs placebo at week 52. All findings except hand-turning persisted at week 104. DHT sensor-based outcome measures may contribute to quantifying disease progression in clinical research of early-stage, dopaminergic treatment-naïve PD. Clinical Trial Registry Name: ClinicalTrials.gov; Clinical Trial Registry ID: NCT03100149; registered 2017-03-29.

Authors

Institutions

Publication Details

Journal
npj Digital Medicine
Published
2025-06-16
DOI
https://doi.org/10.1038/s41746-025-01572-8
Citations
5
Primary Topic
Parkinson's Disease Mechanisms and Treatments
Type
article
Field-Weighted Citation Impact
6.95

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Exploratory digital outcome measures of motor sign progression in Parkinson’s disease patients treated with prasinezumab

Caroline Weill, Peter Morrison, Elizabeth Peckham, Agnès Poirier et al.
5 citations
npj Digital Medicine
Parkinson's Disease Mechanisms and Treatments
6.95
article

Exploratory digital outcome measures of motor sign progression in Parkinson’s disease patients treated with prasinezumab

Caroline Weill, Peter Morrison, Elizabeth Peckham, Agnès Poirier, Danielle Feigenbaum, Jens Schjodt‐Eriksen, Ferenc Martényi, Andrea A. Kühn, Gloria Martí‐Andrés, Rebecca Finch, Christian Homedes, Emma Moore, Kathrin Brockmann, Friederike Borngräber, Kirsten I. Taylor, M. Kunz, Emmanuelle Schmitt, Irene Litvan, Umberto Spampinato, Jianjun Jiao, Stefan Lambrecht, Carme Brun i Gasca, Johnson Moon, Rajesh Pahwa, Markus Britschgi, Sophie Blondeau, Anke Post, Milan Zimmermann, Anne Boulay, Jeffrey M. Gross, Marzia A. Scelsi, Elmar H. Pinkhardt, Raquel Guimarães‐Costa, Sara Belli, Aaron Ellenbogen, Christoph Mühlberg, Caroline Giordana, Timothy Kilchenmann, Susanne Ostrowitzki, Dylan Trundell, Frederik Fries, Alfons Schnitzler, Meret Martin‐Facklam, Juliana Coleman, Ellen Rose, Annette Janzen, Cecile Paquet Luzy, Jorge U Máñez-Miró, Markus Niggli, Brenton A. Wright, James T. Boyd, Simon Laganiere, Thomas B. Toothaker, Endy Weidinger, Jost‐Julian Rumpf, Sara Lucas del Pozo, Ana Marquès, Valérie Fraix, Kaycee M. Sink, Ashok Sriram, Cheikh Diack, María José Martí Domènech, Cameron Dietiker, Kevin J. Klos, Stéphan Grimaldi, Michael Lindemann, Ethan Brown, Tiphaine Vidal, Ira Goodman, Aris Raad Besharat, Juan Marín‐Lahoz, Inés Esparragosa Vázquez, Sara Meoni, Annabelle Monnet, Cheryl Waters, Sylvia Maaß, Laurent Essioux, Andreas Hartmann, Sebastian Dziadek, Heidi Pape, Samuel Frank, N. Barbet, Frank Boess, Ana Martı́nez, Marianne Manchester, Arturo Hernández, Frédérique Fluchère, Ronald B. Postuma, John Fang, Jonathan Vöglein, Jesus Perez, Pooja Patel, Maya Katz, Silja Kannenberg, Andrea Hahn, Johannes Levin, Sylvain Vergnet, Florian Lipsmeier, Dunia Mon Martinez, Wagner Zago, Srinath Kadimi, Kimberly Kwei, Ekaterina Volkova-Volkmar, Rebecca Kassubek, Anna Castrioto, Jens Ebentheuer, Lisa M. Deuel, Christopher L. Carroll, Chris J. Edgar, Hannah Staunton, Rajeev Kumar, J.M. De La Morena, Justine Chan, Antonio Hernandez, Paulo Fontoura, Sara Eichau, Hanno Svoboda, Giulia D’Urso, Joseph Quinn, Siobhán Ewert, Gennaro Pagano, Elena Moro, Jeanette Baker, Christof Bruecke, Karina Dimenshteyn, Alexander Strasak, Marina Cosgaya, Sagrario Martínez Cortijo, Lydia López Manzanares, Nathalie Pross, Thomas Kustermann, Alexandra Foubert‐Samier, Katerina Mironova, Judith Anzures‐Cabrera, Megana Prasad, Laure Delaby, Daniel Umbricht, Kelly Lyons, Daria Rukina, Sagari Betté, Stefano Zanigni, Andres Deik, Anthony Ciabarra, Laura Casado‐Fernández, Shirin Jadidi, Hélène Catalá, Patricia Krause, David Summers, Neepa Patel, Felix Bernhard, Carolyn Taylor, Lydia Vela, Juergen Dukart, Silke Anna Theresa Weber, Alexandra Samier‐Foubert, Stuart Isaacson, Yolanda Macías, Manpreet Multani, Daniela Samaniego, Ernest Balaguer Martinez, Kerstin Schweyer, Karlo J. Lizárraga, Marina Peball, Marie-Helene Delfini, Lynne Verselis, Christian Czech, Pawel M. Kaminski, Štefan Holiga, Marie Fournier, Erin T. Reuther, Hayet Salhi, María de Toledo, Holly A. Shill, Thomas Gasser, Brice Laurens, Karla Eggert, Rachelle S. Doody, Gerrit Machetanz, Jorge Hernández‐Vara, Joseph Jankovic, Günter U. Höglinger, Raphaele Arrouasse, Valérie Cosson, X. Joseph, Stephen S. Klos, A Gorospe, Andrew Billnitzer, Álvaro Sánchez‐Ferro, David H. Russell, Benedicte Ricci, Tatiana Witjas, Amélie Bichon, Isabelle Bénatru, Lille Kurvits, Andrew D. Siderowf, Edilio Borroni, Benjamin Röeben, Jennifer I. Hui, Terry Peery, Louise‐Laure Mariani, Natividad Stover, Katherine Longardner, Werner Popp, Cécile Preterre, Jaime Kulisevsky Bojarsky, Matthew Brodsky, Kathrin Marini, Julio Dotor, Robert A. Hauser, Yaroslau Compta, Isabel Wurster, Atieh Bamdadian, Fabienne Calvas, Travis Hassell, Tania Nikolcheva, Nabila Dahodwala, Monica Canelo, Philippe Damier, Rocío López, David Maltête, Philipp Ellmerer, Arjun Tarakad, Ryan R. Walsh, Philippe Remy, Klaus Seppi, Chantelle Anandan, Dennis Deptula, Azad Bonni, Oliver Schorr, Wassilios G. Meissner, Robert R. Coleman, Julius Huebl, Gurutz Linazasoro Cristóbal, Julie Schwartzbard, Marie Goubeaud, Nima Shariati, Rafael Zuzuarregui, Olivier Rascol, Audrey Petit, Christian J. Hartmann, Federico Carbone, Thomas Boraud, Sana Aslam, Gregor Wenzel, Oren Levy, Joseph Claßen, Thomas Kremer, Michael Honer, Patricia L. Witt, Markus Abt, Maddalena Marchesi, Shadi Barbu, David Grabli, Marissa Dean, Samia Cheriet, Pascal Derkinderen, Franck Durif, Eve Benchetrit, Bérengère Debilly, Evan Davies, Jeff Sevigny, Philippe Derost, Anne Gaille Corbille, Christine Murphy, Annamarie Vogt, Anne Fradet, Tanya Simuni, Rafael L. Perez, Nijee Luthra, Andrea Horta, Elsa Pomies, Danny Bega, Elodie David, Thomas L. Davis, Janet Gibbons, Nadège Van Blercom, Gary R. Andrews, Teresa Barata, Cornelia Weber, Solène Ansquer, J.L. Houéto, Irene Hegeman Richard, Alexandre Eusébio, Christine M. Schubert, Werner Poewe, Jean-Christophe Corvol, Caroline Tanner, H. Marco, Anthony P. Nicholas, Mangone Graziella, Christopher Kobet, Jennifer Koebert, Claudia Altendorf, Maria Rosario Luquin Puido, Antonio Palasis, Jean-Philippe Azula, Victoria Sergo, Claire Thalamus, Nora Vanegas-Arrogave, Mirko Wegschneider, Kara Bardram, Morgan Farell, Waltraud Gruenbauer, Claire Landsdall, Benedicte Passemard, Christoph Sarry, Catherine Casse-Parrot, Janell DeGiorgio, Claudia Eickoff, Monique Gailitzky
article en
5 citations

Abstract

Digital health technology (DHT) tools for Parkinson's disease (PD) e.g., smartphones and wearables were used for remote and frequent measurement of motor signs in the phase 2 PASADENA study of the anti-alpha-synuclein monoclonal antibody prasinezumab. 316 early-stage PD participants were randomized to placebo, 1500 mg, or 4500 mg prasinezumab for 52 weeks; placebo participants were re-randomized to prasinezumab for the ensuing 52 weeks. Patients performed daily smartphone motor "active tests", and were passively monitored by smartphone/smartwatch throughout the day over 2 y. Change from baseline analyses censored data at dopaminergic treatment start. Bilateral speeded tapping variability and hand-turning, U-turn speed, passively monitored hand movement power, and summary Simple Sum scores progressed numerically less in prasinezumab-treated vs placebo at week 52. All findings except hand-turning persisted at week 104. DHT sensor-based outcome measures may contribute to quantifying disease progression in clinical research of early-stage, dopaminergic treatment-naïve PD. Clinical Trial Registry Name: ClinicalTrials.gov; Clinical Trial Registry ID: NCT03100149; registered 2017-03-29.

npj Digital MedicineVol. 8(1)
Florida Institute of Technology (US), University of Vermont (US), Northwestern University (US), University of Southern California (US), Roche (Switzerland) (CH), Fullerton College (US), Hebron University (PS), Beth Israel Deaconess Medical Center (US), Barrow Neurological Institute (US), University of Alabama at Birmingham Hospital (US), Innsbruck Medical University (AT), Henry Ford Health System (US), Institut Pasteur (FR), Philipps University of Marburg (DE), Oregon Health & Science University (US), University of California, San Francisco (US), Baylor College of Medicine (US), University of Exeter (GB), University of South Florida (US), Montreal General Hospital (CA), Hospital de Sant Pau (ES), TUM Klinikum (DE), University of Rochester Medical Center (US), Université de Poitiers (FR), University of California San Diego (US), Sorbonne Université (FR), Assistance Publique Hôpitaux de Marseille (FR), Quest Research Institute (US), Allergy Clinic of Tulsa (US), Compass Research (US), Düsseldorf University Hospital (DE), Hôpital Charles-Nicolle (FR), Hospital Universitario Virgen Macarena (ES), Prothena (United States) (US), Central Texas Neurology Consultants (US), Hospital Universitario Fundación Alcorcón (ES), Aventura Hospital and Medical Center (US), Centre for Movement Disorders (CA), Southern California Clinical and Translational Science Institute (US), Hôpital Pellegrin (FR), Roche (United Kingdom) (GB), Hospital Clínic de Barcelona (ES), Institut Génétique Nantes Atlantique (FR), Hospital General de Catalunya (ES), Policlínica Gipuzkoa (ES), Pitié-Salpêtrière Hospital (FR), Paracelsus Elena Klinik Kassel (DE), Invicro (United States) (US), University Children's Hospital Tübingen (DE), University Hospital Leipzig (DE), Parkinson's Research and Education Foundation (US), Vall d'Hebron Hospital Universitari (ES), University of Kansas Medical Center (US), Centre Hospitalier Universitaire de Clermont-Ferrand (FR), Hôpitaux Universitaires Henri-Mondor (FR), Hospital Universitario de La Princesa (ES), Hôpital Purpan (FR), Hôpital Pasteur (FR), Spectrum Research (United States) (US), University Hospital Ulm (DE), Rocky Mountain MS Center (US), Chiesi (United Kingdom) (GB), Hôpital Laennec (FR), Hôpital Albert Michallon (FR), Associated Neurologists of Southern Connecticut (US), Heinrich Heine University Düsseldorf (DE), McGill University (CA), Phillips University (US), Université de Rouen Normandie (FR), Columbia University (US), Charité - Universitätsmedizin Berlin (DE), Universidad de Sevilla (ES), University of Pennsylvania (US), Universidad de Navarra (ES), Université Grenoble Alpes (FR), Vanderbilt University Medical Center (US)
F. Hoffmann-La Roche, Prothena
Openalex Percentile: Top 3%
Parkinson's Disease Mechanisms and Treatments
6.95
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.